Preprints.org
March 24, 2021
Lehel Balogh, Masaru Tanaka, Nóra Török et al.
22 citations
preprint
Existential phenomenological psychotherapy (EPP) helps people with mood and anxiety disorders find meaning and purpose in life. This narrative review describes EPP's development from the works of Heidegger, Binswanger, Boss, and Frankl, its therapeutic methods, and evidence for its effectiveness. The authors argue that EPP can work synergistically with medication-based treatments for these disorders. They also discuss how neuroscience currently understands mood and anxiety disorders and propose a path to integrate meaning-centered psychotherapy with neuroscience, despite the two fields remaining polarized.
Preprints.org
January 24, 2019
Genís Ona, José Carlos Bouso
8 citations
preprint
The current crisis in psychopharmacology has deep historical roots and requires innovative approaches. The therapeutic use of psychedelic drugs offers a promising and integrative treatment with enduring effects for mental health problems.
Preprints.org
November 28, 2025
Ngo Cheung
6 citations
preprint
An oral glutamatergic regimen combining dextromethorphan, a CYP2D6 inhibitor, piracetam, and l-glutamine shows promise for treating refractory mood and anxiety disorders, with case reports and small open series describing sudden, occasionally dramatic recoveries in depression, PTSD, chronic pain, and functional somatic syndromes. However, the pharmacokinetics require careful handling because the CYP2D6 blocker that maintains dextromethorphan levels can also push the drug or co-prescribed psychotropics into toxic territory, limiting the regimen's accessibility despite its potential to bring rapid-acting biology to outpatient clinics.
Preprints.org
November 25, 2025
Ngo Cheung
6 citations
preprint
Rapid-acting antidepressants can lift mood within hours by shifting glutamatergic circuits from an NMDA-dominant to an AMPA-dominant state. Intravenous ketamine achieves this but has dissociative side effects and logistical challenges; the oral combination dextromethorphan + bupropion (Auvelity) only provides initial NMDA blockade, yielding slower, less durable benefit. A proposed fully oral, low-cost, four-component regimen aims to replicate ketamine's plasticity cascade: dextromethorphan for fast NMDA antagonism, a strong CYP2D6 inhibitor to prolong DXM exposure, the AMPA positive allosteric modulator piracetam to amplify downstream glutamate burst, and micronized L-glutamine to restore presynaptic glutamate pools and buffer against excitotoxicity. Preclinical evidence suggests each element synergizes along the same mechanistic axis, potentially democratizing ketamine-level efficacy with inexpensive medications.
Preprints.org
Enzo Tagliazucchi
2 citations
preprint
Serotonergic psychedelics alter conscious awareness, perception, mood, emotion, and cognition, but their effects resist simple classification like stimulant or sedative. Their defining feature is temporarily inducing an altered state of consciousness. Because only humans can explicitly report conscious experiences, studying these compounds requires non-invasive neuroimaging techniques in healthy subjects. This review examines how neuroimaging has been applied to investigate the neural correlates of altered consciousness caused by serotonergic psychedelics.
Preprints.org
December 22, 2025
Ngo Cheung
1 citation
preprint
Obsessive-compulsive disorder remains treatment-resistant in 40–60% of patients despite optimized serotonin-reuptake inhibitor therapy and antipsychotic augmentation. Emerging evidence points to glutamatergic dysregulation in cortico-striato-thalamo-cortical circuits as a core driver of rigid, maladaptive synaptic patterns. The Cheung Glutamatergic Regimen—a fully oral, low-cost combination of dextromethorphan, a CYP2D6 inhibitor, piracetam, and optional L-glutamine—aims to replicate the rapid neuroplastic cascade triggered by intravenous ketamine.
Preprints.org
December 2, 2025
Ngo Cheung
1 citation
preprint
A 48-year-old man with treatment-resistant depression experienced dramatic mood improvement and elimination of suicidal thoughts after a single dose of intranasal esketamine, but the high cost (HK $6,000 per session) forced him to stop treatment. Over two years, his condition evolved into severe obsessive-compulsive disorder with violent intrusive images. In 2025, he was switched to an oral regimen designed to mimic ketamine's mechanism: dextromethorphan 120 mg/day, fluoxetine 20–40 mg/day, and piracetam 1.2 g/day. Within four weeks, intrusive imagery became sporadic, his PHQ-9 score dropped from 17 to 5–6, suicidal ideation disappeared, and he returned to full work productivity. Gains persisted for over eight months at a monthly cost of HK $400–600, less than one-tenth the cost of maintenance esketamine.
Preprints.org
June 19, 2025
Danial Daroui, Andrea Mastrostefano, Flavio Davini et al.
1 citation
preprint
Psilocybin, when paired with psychotherapy, reduces heavy drinking days and alcohol-related and mental problems in people with Alcohol Use Disorder (AUD), according to a scoping review of 12 studies published between 1968 and 2025. The review included 7 randomized controlled trials, 4 open-label studies, and 1 case report. Early Polish studies suggested long-term remission of alcohol cravings, while recent U.S.-based RCTs confirmed reductions in heavy drinking and associated problems. Limitations include small sample sizes and short follow-up periods, especially for patients with comorbidities. Most studies were conducted in hospital and university psychiatry departments. Psilocybin remains an experimental treatment requiring further rigorous research on efficacy and safety.
Preprints.org
June 17, 2025
Latha Poonamallee
1 citation
preprint
Mindfulness can foster pro-environmental behaviors by enhancing ecological awareness and emotional regulation, offering an alternative to fear-based climate narratives that often cause disengagement and eco-anxiety. Drawing on empirical studies and theoretical frameworks, the paper explores mechanisms such as intrinsic motivation, connectedness to nature, and cognitive flexibility. Applications in organizational and educational settings are discussed, along with barriers to sustained change. Future research directions and strategies for integrating mindfulness into systemic environmental initiatives are identified, positioning it as a critical tool for addressing the global climate crisis.
Preprints.org
October 17, 2024
Tamara Valdez, Valbhi Patel, Dally Senesombath et al.
1 citation
preprint
Psychedelics are being reconsidered as treatments for substance use disorders (SUDs) such as alcohol and opioid use disorders, following early 20th-century anecdotal reports and pilot studies that suggested their potential. Legal restrictions and stigma had halted research, but rising rates of SUDs have renewed interest in these compounds. This review examines emerging evidence for psilocybin, ketamine, LSD, MDMA, ayahuasca, ibogaine, and peyote in treating SUDs, focusing on novel pharmacological targets and holistic approaches to improve adherence and efficacy.
Preprints.org
August 7, 2024
Maria Margariti, Ilias Vlachos, Dimitra Mpourazana et al.
1 citation
preprint
Psychotic arousal is a proposed emotional state during acute psychosis, characterized by abnormal experiential feelings. A new scale, the Psychotic Arousal Scale (PAS), was tested in 55 patients with acute schizophrenia. The scale showed good internal reliability and correlated with measures of delusion conviction, anxiety, and depression. Psychotic arousal decreased with antipsychotic treatment in the first weeks. The findings suggest that emotional arousal with abnormal feelings is present in acute psychosis but often overlooked.
Preprints.org
June 27, 2024
Konstantinos Zorbas
1 citation
preprint
In Tuva Republic, South Siberia, accusations of magical assault and vampirism commonly explain misfortune. Based on fieldwork in an Association of Shamans, this article examines countercursing rituals against antagonists under Russian political domination. It argues that shamanic healing gains efficacy by appropriating hunting symbols and animal spirits from Indigenous Siberian cosmologies. The analysis shows that playing with risk during countercursing structures symbolic resolution. The article concludes that indigenous perceptions of a cursed landscape become a field where agencies of darkness—and their political sponsors—are confronted by an emancipating Buddhist religious mindset.
Preprints.org
October 12, 2023
1 citation
preprint
An 8-week programme combining Zen meditation and music listening enhanced mindfulness and happiness among university music therapy students. Participants reported positive responses to daily stressors such as exam anxiety, financial difficulties, and emotional distress during the COVID-19 pandemic. The qualitative study used surveys and semi-structured interviews, analyzed through thematic analysis, to explore the effects of the meditation and music intervention. The findings suggest that integrating these practices can support mental health and well-being in higher education, offering coping strategies and expanding the potential for combined music and meditation interventions.
Preprints.org
June 6, 2023
Sanah Malomile Nkadimeng, Christiaan M.l. Steinmann, J.n. Eloff
1 citation
preprint
Extracts from four psilocybin-containing mushrooms—Panaeolus cyanescens, Psilocybe natalensis, Psilocybe cubensis, and Psilocybe cubensis leucistic A+ strain—did not worsen angiotensin II-induced cardiac hypertrophy in rat heart cells and instead showed protective effects against oxidative stress. Angiotensin II reduced cell viability, increased cell width, and raised reactive oxygen species levels. The mushroom extracts, prepared with ethanol, cold water, or hot water, did not exacerbate these changes; they exhibited cardio-protective activity. Losartan, an angiotensin receptor blocker, served as a positive control. Phytochemical analysis detected known antioxidant and anti-inflammatory compounds in the extracts.
Preprints.org
July 5, 2022
Ravi Philip Rajkumar
1 citation
preprint
Suicidal behavior is a growing public health problem. Existing treatments have limited effectiveness for people who have already attempted suicide, so new approaches are needed. Research on the neurobiology of social pain—the distress from social rejection or loss—identifies it as a key risk factor and suggests several promising drug targets. This paper reviews evidence on those targets and examines how recently approved treatments like ketamine and psilocybin may reduce suicidal ideation and behavior in the short term, especially when social pain is a contributing factor. These pharmacological strategies may work regardless of whether a person has a specific psychiatric diagnosis.
Preprints.org
September 7, 2021
S. Amigó
1 citation
preprint
A brief psychological intervention called Self-Regulation Therapy (SRT), which uses suggestion and classical conditioning to reproduce the positive effects of illegal drugs (cannabis, cocaine, ecstasy), improved coping with stress and emotionality. Fifteen volunteers (average age 24.67) showed superior coping strategies and positive emotionality, with reduced negative emotionality, compared to no intervention. Improvements persisted during a 4-week follow-up. The findings suggest that reproducing the positive effects of such drugs via SRT can enhance young people's coping and emotional regulation.
Preprints.org
June 28, 2021
Maurizio Coppola, Francesco Bevione, Raffaella Mondola
1 citation
preprint
Psychedelics from plants have been used for millennia in religious and spiritual practices. In 1957, Dr. Hofmann identified and synthesized psilocybin, a prodrug found in over 200 species of psychedelic mushrooms. Despite limitations in study design, clinical observations from the 1950s and 1960s suggested psilocybin had potential therapeutic effects for depressive symptoms, anxiety, and conversion disorder. Classified as a Schedule I substance in 1970, scientific interest revived in the 1990s. Recent studies provide further evidence supporting the hypothesis that psilocybin may be useful for treating psychiatric disorders such as pathological anxiety, mood depressive disorder, and addiction.
Preprints.org
Kainat Riaz, Sejal Suneel, Mohammad Hamza Bin Abdul Malik et al.
1 citation
preprint
Half of patients with post-traumatic stress disorder (PTSD) do not respond to standard pharmacotherapy or psychotherapy. A review of six phase II randomized controlled trials indicates that MDMA-assisted psychotherapy can reduce PTSD symptoms, even in treatment-resistant cases, by increasing neurohormones such as dopamine, serotonin, norepinephrine, and oxytocin and by modulating brain regions involved in fear and anxiety. The FDA has granted MDMA-assisted psychotherapy a "Breakthrough Therapy" designation. Further research is needed to determine whether the benefits outweigh the risks and whether this approach can be integrated into existing treatment options.
Preprints.org
July 3, 2026
preprint
In a ketamine-induced schizophrenic model using Wistar rats, ketamine administration caused significant biochemical and histopathological changes in the kidney and liver. Biochemical analyses revealed elevated markers of kidney and liver damage, while histopathological examination showed structural alterations in both organs. These findings suggest that ketamine, used to model schizophrenia, induces toxicity in the kidney and liver, indicating potential organ damage associated with the model.
Preprints.org
June 30, 2026
preprint
Ketamine shows antidepressant effects by blocking NMDA receptors and promoting neuroplasticity. Combining it with psychotherapy may enhance treatment for depression, trauma, addiction, and other serious conditions by temporarily disrupting rigid thought patterns and enabling new cognitive and emotional connections. This approach remains experimental and is recommended only after standard treatments fail. The article outlines the neurobiological basis of altered states of consciousness and presents initial clinical experience with ketamine-augmented hypnotherapy (KAHT) as one specific method of ketamine-assisted psychotherapy.
Preprints.org
June 23, 2026
preprint
Consciousness remains a major challenge across neuroscience, philosophy, and cognitive science. This review evaluates several leading theories—Global Neuronal Workspace Theory, Integrated Information Theory, Recurrent Processing Theory, Dendritic Integration Theory, Predictive Processing, and the Memory Theory of Consciousness—by examining their philosophical foundations, core claims, and empirical evidence. It focuses on how each theory addresses phenomenal consciousness (subjective experience) and access consciousness (information available for cognition and behavior). Comparing convergent and divergent predictions reveals areas of agreement, ongoing debates, and unresolved questions. The analysis suggests consciousness likely involves multiple interacting neural mechanisms across different spatial and temporal scales, highlighting the need for continued interdisciplinary research.
Preprints.org
June 22, 2026
Andrzej Günther, Barbara Bednarczyk-Cwynar
preprint
The ratio of ibotenic acid to muscimol in Amanita muscaria mushrooms may be a dynamic marker influenced by environmental and post-harvest conditions, rather than a fixed species trait. Ibotenic acid has excitatory glutamatergic effects, while muscimol is a potent GABAergic compound, and ibotenic acid can convert to muscimol through decarboxylation. Abiotic stressors like temperature, drought, and soil chemistry, along with biotic factors such as microbial interactions and host-tree physiology, may affect the biosynthesis and transformation of these compounds. Post-harvest processes like drying, heating, and storage can further alter their ratio, potentially shifting neurotoxicological outcomes between excitatory and inhibitory effects. Direct controlled studies linking specific stressors to ibotenic acid biosynthesis remain limited.
Preprints.org
June 10, 2026
Marcelo Kuna
preprint
The essay argues that the Afro-Brazilian spirit Pombagira—a female enchantress associated with healing and sex, often cast as evil in patriarchal narratives—functions as a decolonial emblem that queers rigid binary categories of womanhood. Drawing on occulture and decolonial theory, the author shows how this figure appears in opera, musical theatre, and film, including Verdi's La forza del destino, Bizet's Carmen, and cinematic Lola characters. The analysis connects Gloria Anzaldúa's queer feminist spiritual mestizaje to Pombagira as an anti-patriarchal force, challenging Western gendered impositions and the epistemicide of Afro-Brazilian traditions.
Preprints.org
April 29, 2026
Stefano Marini, Domenico de Berardis
preprint
Psychedelic drugs, both natural and synthetic, act on serotonin receptors and may enhance cognition, brain connectivity, neuroplasticity, and neuronal regeneration. Autism spectrum disorder involves social communication difficulties and repetitive behaviors, with no approved drugs for core symptoms. Current treatments for co-occurring conditions often have uncertain efficacy and tolerability. This review reports studies indicating that psychedelics could be therapeutically useful for some autism-related symptoms, suggesting a potential role in treatment.
Preprints.org
April 20, 2026
preprint
Medical regulation of psilocybin-assisted therapy has expanded internationally in the past year, with new or clarified regulatory pathways in New Zealand, Germany, Switzerland, the Czech Republic, and at the U.S. federal level. Within the United States, Utah and New Mexico have joined Oregon and Colorado in establishing lawful medical access pathways. These developments build on earlier reforms in Alberta, Canada, and Australia, where structured psychiatric prescribing frameworks were implemented. This update consolidates recent statutory amendments and regulatory decisions to provide a current comparative overview of jurisdictions permitting lawful medical use of psilocybin, distinguishing comprehensive medical regulation from restricted or exceptional access schemes.